Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 584,300 shares, a decline of 14.5% from the May 31st total of 683,200 shares. Based on an average trading volume of 565,000 shares, the short-interest ratio is presently 1.0 days. Approximately 3.5% of the shares of the company are sold short.
Theriva Biologics Stock Performance
NYSEAMERICAN TOVX remained flat at $0.24 during trading on Monday. 70,829 shares of the company’s stock were exchanged, compared to its average volume of 343,720. The company has a current ratio of 3.60, a quick ratio of 3.60 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $4.17 million, a price-to-earnings ratio of -0.21 and a beta of 1.38. Theriva Biologics has a one year low of $0.20 and a one year high of $1.01.
Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter.
About Theriva Biologics
Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.
See Also
- Five stocks we like better than Theriva Biologics
- Insider Buying Explained: What Investors Need to Know
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Investing in the High PE Growth Stocks
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Technology Stocks Explained: Here’s What to Know About Tech
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.